Prevention and treatment of chronic graft-versus-host disease by mesenchymal stem cells: advances and challenges

Bao Yingying; Chen Xiaoyong

doi:10.3969/j.issn.1674-7445.2023.03.002

Volume 14 Issue 3

May 2023

Turn off MathJax

Article Contents

Article Navigation > ORGAN TRANSPLANTATION > 2023 > 14(3): 327-335

Bao Yingying, Chen Xiaoyong. Prevention and treatment of chronic graft-versus-host disease by mesenchymal stem cells: advances and challenges[J]. ORGAN TRANSPLANTATION, 2023, 14(3): 327-335. doi: 10.3969/j.issn.1674-7445.2023.03.002

Citation:

PDF( 2176 KB)

Prevention and treatment of chronic graft-versus-host disease by mesenchymal stem cells: advances and challenges

doi: 10.3969/j.issn.1674-7445.2023.03.002

Bao Yingying^,,
Chen Xiaoyong^{,
,}

Key Laboratory for Stem Cells and Tissue Engineering, Ministry of Education, Sun Yat-sen University, Guangzhou 510080, China

More Information

Corresponding author: Chen Xiaoyong, Email: chenxiaoy@mail.sysu.edu.cn
Received Date: 2023-01-16
Publish Date: 2023-05-15

Abstract

Abstract

Chronic graft-versus-host disease (cGVHD) is the main complication after allogeneic hematopoietic stem cell transplantation, which is also the major cause of non-relapse -related death. Due to its complex pathophysiological process, the response rate of conventional glucocorticoids combined with immunosuppressants is less than 50%. Second-line therapy should be given for patients with glucocorticoid-resistant cGVHD. Nevertheless, no consensus has been reached on current second-line therapy and the therapeutic effect is relatively poor. Mesenchymal stem cell (MSC) is one of the most common adult stem cells. Due to multi-dimensional and multi-target immune regulating function, MSC has been widely applied in the prevention and treatment of cGVHD. In addition, accumulated studies have confirmed the safety and efficacy of MSC in the treatment of cGVHD, which is expected to become a novel strategy for the prevention and management of cGVHD. In this article, research progress, mechanism and existing problems of prevention and treatment of cGVHD by MSC were reviewed, aiming to provide novel ideas for optimizing therapeutic regimens of MSC and enhancing the prevention and treatment effect of cGVHD in subsequent research.
- Allogeneic hematopoietic stem cell transplantation,
- Chronic graft-versus-host disease,
- Mesenchymal stem cell,
- Immune regulation,
- B cell homeostasis,
- Immune tolerance,
- Fibrosis,
- Biomarker

FullText(HTML)

References(48)

References

[1]	ARAI S, ARORA M, WANG T, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research[J]. Biol Blood Marrow Transplant, 2015, 21(2): 266-274. DOI: 10.1016/j.bbmt.2014.10.021.
[2]	PENACK O, MARCHETTI M, RUUTU T, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation[J]. Lancet Haematol, 2020, 7(2): e157-e167. DOI: 10.1016/S2352-3026(19)30256-X.
[3]	JIANG H, FU D, BIDGOLI A, et al. T cell subsets in graft versus host disease and graft versus tumor[J]. Front Immunol, 2021, 12: 761448. DOI: 10.3389/fimmu.2021.761448.
[4]	HILL GR, BETTS BC, TKACHEV V, et al. Current concepts and advances in graft-versus-host disease immunology[J]. Annu Rev Immunol, 2021, 39: 19-49. DOI: 10.1146/annurev-immunol-102119-073227.
[5]	ZEISER R, BLAZAR BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets[J]. N Engl J Med, 2017, 377(26): 2565-2579. DOI: 10.1056/NEJMra1703472.
[6]	HU C, WU Z, LI L. Mesenchymal stromal cells promote liver regeneration through regulation of immune cells[J]. Int J Biol Sci, 2020, 16(5): 893-903. DOI: 10.7150/ijbs.39725.
[7]	SONG N, SCHOLTEMEIJER M, SHAH K. Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential[J]. Trends Pharmacol Sci, 2020, 41(9): 653-664. DOI: 10.1016/j.tips.2020.06.009.
[8]	LE BLANC K, RASMUSSON I, SUNDBERG B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells[J]. Lancet, 2004, 363(9419): 1439-1441. DOI: 10.1016/S0140-6736(04)16104-7.
[9]	MACÍAS-SÁNCHEZ MDM, MORATA-TARIFA C, CUENDE N, et al. Mesenchymal stromal cells for treating steroid-resistant acute and chronic graft versus host disease: a multicenter compassionate use experience[J]. Stem Cells Transl Med, 2022, 11(4): 343-355. DOI: 10.1093/stcltm/szac003.
[10]	LIU K, CHEN Y, ZENG Y, et al. Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: a randomized, controlled clinical study[J]. Stem Cells Dev, 2011, 20(10): 1679-1685. DOI: 10.1089/scd.2010.0447.
[11]	MACMILLAN ML, BLAZAR BR, DEFOR TE, et al. Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-Ⅱ clinical trial[J]. Bone Marrow Transplant, 2009, 43(6): 447-454. DOI: 10.1038/bmt.2008.348.
[12]	BERNARDO ME, BALL LM, COMETA AM, et al. Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation[J]. Bone Marrow Transplant, 2011, 46(2): 200-207. DOI: 10.1038/bmt.2010.87.
[13]	GAO L, ZHANG Y, HU B, et al. Phase Ⅱ multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord-derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem-cell transplantation[J]. J Clin Oncol, 2016, 34(24): 2843-2850. DOI: 10.1200/JCO.2015.65.3642.
[14]	WANG Q, XU N, WANG Y, et al. Allogeneic stem cell transplantation combined with transfusion of mesenchymal stem cells in primary myelofibrosis: a multicenter retrospective study[J]. Front Oncol, 2022, 11: 792142. DOI: 10.3389/fonc.2021.792142.
[15]	ZHAO K, LIN R, FAN Z, et al. Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial[J]. J Hematol Oncol, 2022, 15(1): 22. DOI: 10.1186/s13045-022-01240-4.
[16]	WANG L, ZHU CY, MA DX, et al. Efficacy and safety of mesenchymal stromal cells for the prophylaxis of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials[J]. Ann Hematol, 2018, 97(10): 1941-1950. DOI: 10.1007/s00277-018-3384-8.
[17]	MORATA-TARIFA C, MACÍAS-SÁNCHEZ MDM, GUTIÉRREZ-PIZARRAYA A, et al. Mesenchymal stromal cells for the prophylaxis and treatment of graft-versus-host disease-a meta-analysis[J]. Stem Cell Res Ther, 2020, 11(1): 64. DOI: 10.1186/s13287-020-01592-z.
[18]	FISHER SA, CUTLER A, DOREE C, et al. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition[J]. Cochrane Database Syst Rev, 2019, 1(1): CD009768. DOI: 10.1002/14651858.CD009768.pub2.
[19]	LI T, LUO C, ZHANG J, et al. Efficacy and safety of mesenchymal stem cells co-infusion in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis[J]. Stem Cell Res Ther, 2021, 12(1): 246. DOI: 10.1186/s13287-021-02304-x.
[20]	WANG Z, YU H, CAO F, et al. Donor-derived marrow mesenchymal stromal cell co-transplantation following a haploidentical hematopoietic stem cell transplantation trail to treat severe aplastic anemia in children[J]. Ann Hematol, 2019, 98(2): 473-479. DOI: 10.1007/s00277-018-3523-2.
[21]	MÜLLER I, KORDOWICH S, HOLZWARTH C, et al. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation[J]. Blood Cells Mol Dis, 2008, 40(1): 25-32. DOI: 10.1016/j.bcmd.2007.06.021.
[22]	WENG JY, DU X, GENG SX, et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD[J]. Bone Marrow Transplant, 2010, 45(12): 1732-1740. DOI: 10.1038/bmt.2010.195.
[23]	JURADO M, DE LA MATA C, RUIZ-GARCÍA A, et al. Adipose tissue-derived mesenchymal stromal cells as part of therapy for chronic graft-versus-host disease: a phase I/Ⅱ study[J]. Cytotherapy, 2017, 19(8): 927-936. DOI: 10.1016/j.jcyt.2017.05.002.
[24]	BOBERG E, VON BAHR L, AFRAM G, et al. Treatment of chronic GVHD with mesenchymal stromal cells induces durable responses: a phase Ⅱ study[J]. Stem Cells Transl Med, 2020, 9(10): 1190-1202. DOI: 10.1002/sctm.20-0099.
[25]	ZHOU T, HE C, LAI P, et al. miR-204-containing exosomes ameliorate GVHD-associated dry eye disease[J]. Sci Adv, 2022, 8(2): eabj9617. DOI: 10.1126/sciadv.abj9617.
[26]	CHEN S, ZHAO K, LIN R, et al. The efficacy of mesenchymal stem cells in bronchiolitis obliterans syndrome after allogeneic HSCT: a multicenter prospective cohort study[J]. EbioMedicine, 2019, 49: 213-222. DOI: 10.1016/j.ebiom.2019.09.039.
[27]	PENG Y, CHEN X, LIU Q, et al. Alteration of naïve and memory B-cell subset in chronic graft-versus-host disease patients after treatment with mesenchymal stromal cells[J]. Stem Cells Transl Med, 2014, 3(9): 1023-1031. DOI: 10.5966/sctm.2014-0001.
[28]	PENG Y, CHEN X, LIU Q, et al. Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5⁺ regulatory B cells producing interleukin 10[J]. Leukemia, 2015, 29(3): 636-646. DOI: 10.1038/leu.2014.225.
[29]	STENGER E, GIVER CR, LANGSTON A, et al. Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease[J]. Front Immunol, 2022, 13: 959658. DOI: 10.3389/fimmu.2022.959658.
[30]	ZHANG X, ZHAO K, HE JB, et al. Mesenchymal stem cells improve the structure and function of the graft-versus-host disease receptor thymus: CCR9 plays an important role in its homing thymus[J]. Blood, 2019, 134(Suppl 1): 5599. DOI: 10.1182/blood-2019-125307.
[31]	LAI P, CHEN X, GUO L, et al. A potent immunomodulatory role of exosomes derived from mesenchymal stromal cells in preventing cGVHD[J]. J Hematol Oncol, 2018, 11(1): 135. DOI: 10.1186/s13045-018-0680-7.
[32]	ROZMUS J, KARIMINIA A, ABDOSSAMADI S, et al. Comprehensive B cell phenotyping profile for chronic graft-versus-host disease diagnosis[J]. Biol Blood Marrow Transplant, 2019, 25(3): 451-458. DOI: 10.1016/j.bbmt.2018.11.007.
[33]	YEHUDAI-OFIR D, HENIG I, ZUCKERMAN T. Aberrant B cells, autoimmunity and the benefit of targeting B cells in chronic graft-versus-host disease[J]. Autoimmun Rev, 2020, 19(4): 102493. DOI: 10.1016/j.autrev.2020.102493.
[34]	SARANTOPOULOS S, RITZ J. Aberrant B-cell homeostasis in chronic GVHD[J]. Blood, 2015, 125(11): 1703-1707. DOI: 10.1182/blood-2014-12-567834.
[35]	JIA W, POE JC, SU H, et al. BAFF promotes heightened BCR responsiveness and manifestations of chronic GVHD after allogeneic stem cell transplantation[J]. Blood, 2021, 137(18): 2544-2557. DOI: 10.1182/blood.2020008040.
[36]	ZHANG M, ZHANG S. T cells in fibrosis and fibrotic diseases[J]. Front Immunol, 2020, 11: 1142. DOI: 10.3389/fimmu.2020.01142.
[37]	GUO L, LAI P, WANG Y, et al. Extracellular vesicles derived from mesenchymal stem cells prevent skin fibrosis in the cGVHD mouse model by suppressing the activation of macrophages and B cells immune response[J]. Int Immunopharmacol, 2020, 84: 106541. DOI: 10.1016/j.intimp.2020.106541.
[38]	MACDONALD KP, HILL GR, BLAZAR BR. Chronic graft-versus-host disease: biological insights from preclinical and clinical studies[J]. Blood, 2017, 129(1): 13-21. DOI: 10.1182/blood-2016-06-686618.
[39]	LI Y, HAO J, HU Z, et al. Current status of clinical trials assessing mesenchymal stem cell therapy for graft versus host disease: a systematic review[J]. Stem Cell Res Ther, 2022, 13(1): 93. DOI: 10.1186/s13287-022-02751-0.
[40]	孙旭燕, 张学娟, 赵江宁, 等. 性别差异对间充质干细胞生物学特性的影响[J/CD]. 中华细胞与干细胞杂志(电子版), 2021, 11(5): 317-320. DOI: 10.3877/cma.j.issn.2095-1221.2021.05.010. SUN XY, ZHANG XJ, ZHAO JN, et al. Effects of gender differences on biological characteristics of mesenchymal stem cells[J/CD]. Chin J Cell Stem Cell (Electr Edit), 2021, 11(5): 317-320. DOI: 10.3877/cma.j.issn.2095-1221.2021.05.010.
[41]	VAN DER WAGEN LE, MIRANDA-BEDATE A, JANSSEN A, et al. Efficacy of MSC for steroid-refractory acute GVHD associates with MSC donor age and a defined molecular profile[J]. Bone Marrow Transplant, 2020, 55(11): 2188-2192. DOI: 10.1038/s41409-020-0910-9.
[42]	TAGO Y, KOBAYASHI C, OGURA M, et al. Human amnion-derived mesenchymal stem cells attenuate xenogeneic graft-versus-host disease by preventing T cell activation and proliferation[J]. Sci Rep, 2021, 11(1): 2406. DOI: 10.1038/s41598-021-81916-y.
[43]	CHEN J, HUANG J, SHI J, et al. Nestin+ Peyer's patch resident MSCs enhance healing of inflammatory bowel disease through IL-22-mediated intestinal epithelial repair[J]. Cell Prolif, 2023, 56(2): e13363. DOI: 10.1111/cpr.13363.
[44]	BIKORIMANA JP, SAAD W, ABUSARAH J, et al. CD146 defines a mesenchymal stromal cell subpopulation with enhanced suppressive properties[J]. Cells, 2022, 11(15): 2263. DOI: 10.3390/cells11152263.
[45]	BOREGOWDA SV, KRISHNAPPA V, HAGA CL, et al. A clinical indications prediction scale based on twist1 for human mesenchymal stem cells[J]. EbioMedicine, 2015, 4: 62-73. DOI: 10.1016/j.ebiom.2015.12.020.
[46]	SHEN MZ, LIU XX, QIU ZY, et al. Efficacy and safety of mesenchymal stem cells treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation[J]. Ther Adv Hematol, 2022, 13: 20406207211072838. DOI: 10.1177/20406207211072838.
[47]	SCHULTZ KR, KARIMINIA A, NG B, et al. Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies[J]. Blood, 2020, 135(15): 1287-1298. DOI: 10.1182/blood.2019003186.
[48]	MILOSEVIC E, BABIC A, IOVINO L, et al. Use of the NIH consensus criteria in cellular and soluble biomarker research in chronic graft-versus-host disease: a systematic review[J]. Front Immunol, 2022, 13: 1033263. DOI: 10.3389/fimmu.2022.1033263.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (525) PDF downloads(86)

Prevention and treatment of chronic graft-versus-host disease by mesenchymal stem cells: advances and challenges

doi: 10.3969/j.issn.1674-7445.2023.03.002

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Prevention and treatment of chronic graft-versus-host disease by mesenchymal stem cells: advances and challenges

doi: 10.3969/j.issn.1674-7445.2023.03.002

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Export File

Citation

Format

Content